Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects

Phase 2

Completed

Conditions: Insulin Resistance
Obesity

First Posted Date: 2005-09-07

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 138

Registration Number: NCT00146289

Locations: 🇨🇦
St. Joseph's Health Care London, London, Ontario, Canada
🇩🇪
Universitätsmedizin Berlin, Berlin, Germany
🇩🇪
Boehringer Ingelheim Investigational Site, Unterschneidheim, Germany

and more 8 locations

Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: Tipranavir

First Posted Date: 2005-09-07

Last Posted Date: 2014-03-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 997

Registration Number: NCT00146328

Locations: 🇺🇸
1182.17.26 Boehringer Ingelheim Investigational Site, Columbus, Ohio, United States
🇺🇸
1182.17.89 Boehringer Ingelheim Investigational Site, Berkeley, California, United States
🇺🇸
1182.17.73 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States

and more 230 locations

Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Failed in Telmisartan 80 mg

Phase 3

Completed

Conditions: Hypertension

First Posted Date: 2005-09-07

Last Posted Date: 2017-12-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 345

Registration Number: NCT00146341

Locations: 🇨🇳
Ruijin Hospital, School of Medicine, Shanghai, China
🇨🇳
No. 1 Hosp Affiliated to Med College, Zhejiang Province, China
🇨🇳
Beijing Tiantan Hospital, Beijing, China

and more 6 locations

Open Label Study of NVP+CBV Treatment in Women Who Have Received sdNVP for the pMTCT of HIV

Phase 4

Completed

Conditions: Acquired Immunodeficiency Syndrome

First Posted Date: 2005-09-05

Last Posted Date: 2013-11-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 53

Registration Number: NCT00144157

Locations: 🇿🇦
Boehringer Ingelheim Investigational Site, Soweto, South Africa

Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy

Phase 3

Completed

Conditions: Hypertension

First Posted Date: 2005-09-05

Last Posted Date: 2013-11-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 218

Registration Number: NCT00144222

Locations: 🇯🇵
Boehringer Ingelheim Investigational Site, Shinjuku-ku, Tokyo, Japan

Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2005-09-05

Last Posted Date: 2013-11-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 255

Registration Number: NCT00144287

Locations: 🇩🇪
Epimed GmbH, Berlin, Germany
🇩🇪
Städtisches Klinikum St. Georg, Leipzig, Germany
🇩🇪
Johannes-Gutenberg-Universität Mainz, Mainz, Germany

and more 25 locations

A Study of Single Dose Nevirapine (NVP) Combined With Combivir® for the Prevention of Mother to Child Transmission (pMTCT) - Treatment Options Preservation Study (TOPS)

Phase 3

Completed

Conditions: Acquired Immunodeficiency Syndrome

First Posted Date: 2005-09-05

Last Posted Date: 2013-11-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 407

Registration Number: NCT00144183

Locations: 🇿🇦
Boehringer Ingelheim Investigational Site, Soweto, South Africa

Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome

Phase 3

Completed

Conditions: Restless Legs Syndrome

First Posted Date: 2005-09-05

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 58

Registration Number: NCT00144209

Locations: 🇨🇭
Boehringer Ingelheim Investigational Site, Zurzach, Switzerland

A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.

Phase 2

Terminated

Conditions: HIV Infections

First Posted Date: 2005-09-05

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 562

Registration Number: NCT00144105

Locations: 🇬🇧
Boehringer Ingelheim Investigational Site, Edinburgh, United Kingdom
🇦🇷
Hospital Posadas, Haedo, Argentina
🇧🇷
Universidade Federal do Rio de Janeiro, Rio de Janeiro - RJ, Brazil

and more 59 locations

Pharmaton Upgrade in Improving Mental Performance and Decreasing Fatigue

Phase 3

Completed

Conditions: Mental Competency
Mental Fatigue

First Posted Date: 2005-09-05

Last Posted Date: 2013-10-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 412

Registration Number: NCT00144235

Locations: 🇬🇧
Boehringer Ingelheim Investigational Site, Aldershot, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy